The fda/panel NEVER voted against a drug which was ALREADY endorsed by all medical org. in that field (nla,ada,adh,acc). In your example the drug was only endorsed by nla at the time fda gave the crl. Also--in Vascepa case the organizations actually included it in their GUIDELINES!! In your drug I do not see such inclusion.